Clinical Trial: Cardiac Biomarkers in Patients Receiving Immune Checkpoint Inhibitors (PRIME-ICI)

U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07864727) titled 'Cardiac Biomarkers in Patients Receiving Immune Checkpoint Inhibitors (PRIME-ICI)' on Oct. 02.

Brief Summary: Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. Blood tests such as cardiac troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) can help clinicians investigate possible heart injury, but these markers may also be raised for other reasons such as infection, kidney dysfunction, arrhythmia, pulmonary embolism or fluid overload. PRIME-ICI is a prospective observational study of adults starting ICI therapy at The James Cook University Hospital. The study will mainly use leftover blood from rou...